---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004474"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:34:45.953755+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Axsome Q4 net product sales $24.4M; Auvelity launch nets $5.2M; Sunosi EU license $66M upfront

## Summary
- Q4 2022 net product sales $24.4M (Auvelity $5.2M, Sunosi $19.2M); full-year net sales $50.0M.
- Q4 net loss $61.2M ($1.41/share) vs $34.0M loss in Q4 2021; full-year loss $187.1M ($4.60/share).
- Sunosi EU license to Pharmanovia: $66M upfront, up to $101M milestones, mid-twenties royalty on net sales.
- Pro forma cash >$300M after $66M upfront and $55M tranche from amended Hercules loan facility.
- Pipeline: AXS-12 narcolepsy Phase 3 topline expected 1H 2023; AXS-07 migraine NDA resubmission 2H 2023.

## SEC filing metadata
- accession: 0000950170-23-004474
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004474/0000950170-23-004474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004474/axsm-20230227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004474
- JSON: https://secwatch.observer/filing/0000950170-23-004474.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004474.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported Fourth quarter 2022 results: revenue $24.4 million, net income Net loss of $61.2 million, EPS $(1.41).
  - Period: Fourth quarter 2022
  - Revenue: $24.4 million
  - Net income: Net loss of $61.2 million
  - EPS: $(1.41)
  - Result: reported results
  source text: Fourth Quarter 2022 Financial Highlights • Total net sales were $24.4 million and $50.0 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. Auvelity was launched on October 19, 2022 and had U.S. net sales of $5.2 million for the fourth quarter of 2022. No Auvelity sales were reported by Axsome for the 2021 comparable period reflecting the timing of the Auvelity approval and launch. Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May 2022 and in certain international markets in November 2022. Therefore no Sunosi sales were reported by Axsome for the 2021 comparable periods. • Total cost of product sales were $2.3 million and $5.2 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. • Research and development (R&D) expenses were $14.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004474/0000950170-23-004474-index.htm
- Earnings Releases
  Axsome Therapeutics, Inc. reported Full year 2022 results: revenue $50.0 million, net income Net loss of $187.1 million, EPS $(4.60).
  - Period: Full year 2022
  - Revenue: $50.0 million
  - Net income: Net loss of $187.1 million
  - EPS: $(4.60)
  - Result: reported results
  source text: Fourth Quarter 2022 Financial Highlights • Total net sales were $24.4 million and $50.0 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. Auvelity was launched on October 19, 2022 and had U.S. net sales of $5.2 million for the fourth quarter of 2022. No Auvelity sales were reported by Axsome for the 2021 comparable period reflecting the timing of the Auvelity approval and launch. Net sales of Sunosi to Axsome were $19.2 million and $44.8 million for the fourth quarter and full year of 2022 respectively. Axsome began selling Sunosi in the U.S. in May 2022 and in certain international markets in November 2022. Therefore no Sunosi sales were reported by Axsome for the 2021 comparable periods. • Total cost of product sales were $2.3 million and $5.2 million for the fourth quarter and full year of 2022 respectively, compared to none for the 2021 comparable periods. • Research and development (R&D) expenses were $14.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023004474/0000950170-23-004474-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.